Profile data is unavailable for this security.
About the company
Warby Parker Inc. is a lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. It offers holistic vision care by selling eyewear products and providing optical services directly to consumers through its retail stores and e-commerce platform. It sells a range of prescription and non-prescription eyewear, including glasses, sunglasses, and contact lenses. Its customers can customize their prescription lenses with a variety of options, including single-vision, progressive, light-responsive, blue-light-filtering, and non-prescription lenses. It also offers in-house technologies like Virtual Vision Test and Virtual Try-On to enhance the overall customer experience. It sells its own brand of contacts, Scout by Warby Parker, and third-party contact lenses; this allows it to provide customers a vision care offering. Its Website and mobile app make it easy for its customers to browse, virtually try on, and purchase glasses.
- Revenue in USD (TTM)742.53m
- Net income in USD-32.56m
- Incorporated2009
- Employees2.14k
- LocationWarby Parker Inc233 Spring Street, 6Th Floor EastNEW YORK 10013United StatesUSA
- Phone+1 (646) 847-7215
- Fax+1 (302) 636-5454
- Websitehttps://www.warbyparker.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10X Genomics Inc | 629.74m | -182.55m | 1.90bn | 1.26k | -- | 2.63 | -- | 3.01 | -1.53 | -1.53 | 5.26 | 5.97 | 0.6677 | 2.40 | 6.72 | 500,193.00 | -19.36 | -25.52 | -21.99 | -29.05 | 66.63 | 75.88 | -28.99 | -48.53 | 4.12 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Integra Lifesciences Holdings Corp | 1.56bn | -6.54m | 1.91bn | 3.95k | -- | 1.26 | 14.99 | 1.22 | -0.0881 | -0.0881 | 20.22 | 19.73 | 0.401 | 1.59 | 5.99 | 396,583.90 | -0.1677 | 3.33 | -0.2002 | 3.68 | 59.29 | 63.67 | -0.4182 | 7.99 | 0.7261 | 4.05 | 0.5428 | 0.00 | -1.03 | 0.9219 | -62.48 | 2.19 | -2.97 | -- |
| Novocure Ltd | 577.74m | -149.78m | 1.93bn | 1.45k | -- | 5.34 | -- | 3.34 | -1.39 | -1.39 | 5.37 | 3.34 | 0.4879 | 3.59 | 8.74 | 397,617.30 | -12.65 | -7.74 | -20.29 | -8.95 | 76.42 | 77.22 | -25.93 | -14.69 | 1.44 | -- | 0.6446 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Tandem Diabetes Care Inc | 854.35m | -126.78m | 2.04bn | 2.40k | -- | 8.59 | -- | 2.39 | -1.94 | -1.94 | 13.08 | 3.62 | 0.9004 | 2.90 | 8.23 | 355,979.60 | -13.36 | -10.08 | -17.47 | -12.23 | 49.79 | 51.77 | -14.84 | -11.59 | 2.32 | -- | 0.5945 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
| Premier Inc | 1.28bn | 147.17m | 2.21bn | 2.90k | 16.62 | 1.15 | 8.41 | 1.73 | 1.38 | 1.37 | 11.65 | 19.98 | 0.3562 | -- | 2.99 | 439,914.10 | 3.83 | 7.08 | 4.78 | 8.95 | 67.24 | 61.29 | 10.76 | 16.05 | -- | -- | 0.2771 | 27.32 | 0.7684 | 2.03 | -31.70 | -11.93 | -2.76 | -- |
| Omnicell Inc | 1.06bn | -17.69m | 2.25bn | 3.66k | -- | 1.84 | 33.88 | 2.11 | -0.3917 | -0.3917 | 23.17 | 26.59 | 0.4704 | 5.90 | 4.06 | 291,563.30 | -0.7817 | 1.73 | -1.11 | 2.25 | 41.44 | 46.69 | -1.66 | 2.92 | 0.9529 | -- | 0.3172 | 0.00 | -11.48 | 7.82 | -460.68 | -- | 0.235 | -- |
| Conmed Corp | 1.29bn | 131.74m | 2.31bn | 4.00k | 17.68 | 2.48 | 11.34 | 1.79 | 4.23 | 4.23 | 41.38 | 30.21 | 0.555 | 1.71 | 5.58 | 322,029.00 | 5.68 | 0.8972 | 6.62 | 1.02 | 55.65 | 54.95 | 10.23 | 1.65 | 1.06 | 5.22 | 0.5021 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
| LeMaitre Vascular Inc | 213.03m | 41.32m | 2.32bn | 614.00 | 56.64 | 7.01 | 45.53 | 10.89 | 1.82 | 1.82 | 9.41 | 14.73 | 0.5992 | 1.11 | 7.59 | 346,952.80 | 11.62 | 9.02 | 12.66 | 9.93 | 68.34 | 65.83 | 19.40 | 15.45 | 5.52 | -- | 0.00 | 40.41 | 19.69 | 12.88 | 45.89 | 5.96 | 18.93 | 15.51 |
| Warby Parker Inc | 742.53m | -32.56m | 2.54bn | 2.14k | -- | 7.58 | 224.29 | 3.43 | -0.2731 | -0.2731 | 6.20 | 2.80 | 1.22 | 5.70 | 818.21 | 346,975.20 | -5.37 | -- | -6.78 | -- | 55.32 | 57.49 | -4.39 | -14.53 | 2.06 | -- | 0.00 | -- | 11.98 | 19.67 | 42.75 | -- | -- | -- |
| Enovis Corp | 2.00bn | -121.38m | 2.62bn | 6.55k | -- | 0.7869 | 17.92 | 1.31 | -2.21 | -2.17 | 36.43 | 59.61 | 0.4023 | 1.59 | 5.91 | 305,598.20 | -2.43 | -0.3569 | -2.66 | -0.41 | 56.96 | 48.19 | -6.03 | -1.06 | 1.12 | 0.9889 | 0.2876 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
| UFP Technologies Inc | 461.85m | 54.21m | 2.64bn | 3.09k | 49.10 | 8.01 | 39.23 | 5.71 | 7.00 | 7.00 | 59.64 | 42.89 | 0.8896 | 4.18 | 6.15 | 149,320.40 | 10.44 | 9.69 | 12.00 | 10.95 | 28.31 | 26.33 | 11.74 | 10.14 | 1.43 | 13.44 | 0.3918 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
| Irhythm Technologies Inc | 560.03m | -150.66m | 2.73bn | 2.00k | -- | 38.02 | -- | 4.87 | -4.85 | -4.85 | 18.04 | 2.29 | 0.83 | 12.56 | 8.79 | 280,012.50 | -22.33 | -21.92 | -26.27 | -26.77 | 67.83 | 69.39 | -26.90 | -25.75 | 6.12 | -24.18 | 0.90 | -- | 19.90 | 27.32 | -6.24 | -- | 50.82 | -- |
| Quidelortho Corp | 2.82bn | -1.87bn | 2.77bn | 7.10k | -- | 0.8676 | -- | 0.9817 | -27.89 | -27.89 | 42.04 | 47.42 | 0.3674 | 2.62 | 7.84 | 396,859.20 | -24.34 | 11.34 | -27.75 | 12.91 | 47.62 | 62.71 | -66.25 | 20.93 | 0.8134 | 0.7419 | 0.4446 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
| LivaNova PLC | 1.24bn | 23.68m | 2.88bn | 2.90k | 124.43 | 2.20 | 42.41 | 2.32 | 0.4259 | 0.4259 | 22.81 | 24.13 | 0.5119 | 2.47 | 6.42 | 428,185.90 | 0.9777 | -6.01 | 1.12 | -7.42 | 67.78 | 66.99 | 1.91 | -13.56 | 2.87 | 2.46 | 0.3234 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
| Inari Medical Inc | 574.50m | -78.58m | 3.00bn | 1.30k | -- | 6.90 | -- | 5.23 | -1.35 | -1.35 | 9.90 | 7.44 | 0.9221 | 1.59 | 7.46 | 441,921.50 | -12.61 | -0.5941 | -15.24 | -0.6696 | 86.82 | 89.06 | -13.68 | -0.6295 | 1.40 | -- | 0.00 | -- | 28.73 | 135.40 | 94.41 | -- | 52.46 | -- |
| TransMedics Group Inc | 401.09m | 32.64m | 3.07bn | 584.00 | 97.36 | 14.61 | 60.82 | 7.65 | 0.9389 | 0.9389 | 11.60 | 6.25 | 0.5439 | 3.56 | 5.32 | 686,797.90 | 4.43 | -16.08 | 4.78 | -17.95 | 59.34 | 65.37 | 8.14 | -40.47 | 7.33 | -- | 0.7078 | -- | 158.53 | 79.36 | 30.92 | -- | 225.12 | -- |
Data as of Nov 13 2024. Currency figures normalised to Warby Parker Inc's reporting currency: US Dollar USD
52.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Aug 2024 | 10.14m | 10.07% |
| D1 Capital Partners LPas of 30 Jun 2024 | 9.44m | 9.38% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 8.89m | 8.83% |
| Durable Capital Partners LPas of 30 Jun 2024 | 6.85m | 6.81% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 6.00m | 5.96% |
| T. Rowe Price Investment Management, Inc.as of 30 Jun 2024 | 2.93m | 2.91% |
| Vaughan Nelson Investment Management LPas of 30 Sep 2024 | 2.56m | 2.54% |
| Baillie Gifford & Co.as of 30 Sep 2024 | 2.20m | 2.18% |
| Gilder, Gagnon, Howe & Co. LLCas of 30 Jun 2024 | 2.14m | 2.13% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.14m | 2.13% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
